Translating “Translation and Diagnostics” – bridging the third translational gap

Lead Research Organisation: Newcastle University

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.  The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities.  This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes.  Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.

Publications

10 25 50
 
Description CRUK Accelerator Award: HUNTER: Hepatocellular Carcinoma Expediter Network
Amount £5,000,000 (GBP)
Funding ID C9380/A28223 & A26813 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2018 
End 11/2023
 
Description Effect of Lonza supplied components (actives/botanicals) on the microbiota of healthy skin- PhD study
Amount £97,507 (GBP)
Organisation Lonza Group 
Sector Private
Country Global
Start 10/2018 
End 09/2021
 
Description Evaluation of nicotine and its analogues to remediate dyskinesias and cognitive deficits associated with Parkinson's disease
Amount £294,180 (GBP)
Funding ID G-1805 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2019 
End 01/2021
 
Description Functional and genomic characterisation of ultraviolet-B on involved and uninvolved psoriatic skin: application towards understanding of environmental stress effects on ageing and cancer risk.
Amount £118,487 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 02/2018 
End 01/2021
 
Description ICURe ASTEROID, the fun 3D eye test.
Amount £29,980 (GBP)
Organisation Higher Education Funding Council for England 
Sector Public
Country United Kingdom
Start 05/2017 
End 08/2017
 
Description ICURe Cohort 8 AMLO-a novel prognostic test for melanoma disease progression
Amount £35,000 (GBP)
Funding ID 08-02/514603916 
Organisation Higher Education Funding Council for England 
Sector Public
Country United Kingdom
Start 03/2017 
End 06/2017
 
Description LITMUS
Amount £3,321,092 (GBP)
Funding ID 777377 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 10/2017 
End 10/2022
 
Description MICA-Molecular drivers of fibrosis at the hepatic epithelial-mesenchymal barrier
Amount £1,871,277 (GBP)
Funding ID MR/R023026/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2019 
End 01/2024
 
Description NICE AdviSeMe Prize for its novel prognostic skin cancer test AMBLor
Amount £15,000 (GBP)
Organisation National Institute for Health and Care Excellence (NICE) 
Sector Public
Country United Kingdom
Start 01/2018 
 
Description NIHR HTA: Optimal surveillance strategies for grade I melanoma: An evidence synthesis and economic modelling
Amount £262,200 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 05/2018 
End 07/2019
 
Description NIHR Senior Investigator Award
Amount £60,000 (GBP)
Funding ID NIHR200168 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2019 
End 03/2023
 
Description Newcastle University EPSRC IAA - Using in silico and cell biology approaches to determine the protective of effects of Hexis Lab provided actives on mitochondrial DNA damage and bioenergy biomarkers in human skin cells subjected to oxidative stress
Amount £23,495 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 12/2017 
End 05/2018
 
Description Newcastle University Northern Accelerator - European Structural and Investment Funds for ALMo
Amount £25,000 (GBP)
Organisation Government of the UK 
Sector Public
Country United Kingdom
Start 09/2017 
End 03/2018
 
Description Towards targeting neutrophils in hepatocellular carcinoma
Amount £941,943 (GBP)
Funding ID C18342/A23390 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 02/2022
 
Description i4i Innovative diagnostic test for early stage, high risk, melanoma AMLo
Amount £1,005,680 (GBP)
Funding ID II-LA-0417-20001 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 06/2018 
End 11/2020
 
Description iCURE - ALMo
Amount £218,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 10/2017 
End 03/2018
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop 
Organisation AbbVie Inc
Department Translational Immunology Department
Country Global 
Sector Private 
PI Contribution Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
Collaborator Contribution The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area.
Impact No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema.
Start Year 2016
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop 
Organisation British Association of Dermatologists (BAD)
Country United Kingdom 
Sector Learned Society 
PI Contribution Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
Collaborator Contribution The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area.
Impact No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema.
Start Year 2016
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop 
Organisation Croda International
Country United Kingdom 
Sector Private 
PI Contribution Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
Collaborator Contribution The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area.
Impact No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema.
Start Year 2016
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop 
Organisation Eczema Outreach (Scotland)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
Collaborator Contribution The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area.
Impact No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema.
Start Year 2016
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
Collaborator Contribution The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area.
Impact No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema.
Start Year 2016
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop 
Organisation LEO Pharma (including subsidiary Peplin Ltd)
Country Denmark 
Sector Private 
PI Contribution Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
Collaborator Contribution The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area.
Impact No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema.
Start Year 2016
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop 
Organisation National Eczema Society
Country United Kingdom 
Sector Learned Society 
PI Contribution Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
Collaborator Contribution The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area.
Impact No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema.
Start Year 2016
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop 
Organisation Sanofi
Country Global 
Sector Private 
PI Contribution Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
Collaborator Contribution The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area.
Impact No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema.
Start Year 2016
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop 
Organisation Wellcome Trust
Department Wellcome Trust Bloomsbury Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Initiated, organised and chaired by Professor Reynolds, the PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
Collaborator Contribution The event was initiated, organised and chaired by Professor Reynolds who also presented at the event. Two further presentations were made by academics from Newcastle University. The contribution from Industry included staff time and expenses to attend the event, including 3 US flights (Abbvie), 1 European (LEO Pharma), and UK based staff travelling to the event. Abbvie estimated that this amounted to an in-kind contribution of £17,800. The British Association of Dermatologists provided staff support in the organisation of the event, and covered the expenses of some of the delegates. They will continue to work with us on future collaborations in this area.
Impact No formal outputs and outcomes at this stage, although it is planned that formal collaborations will continue as a result of the initiative, leading to a UK-wide consortium focused on stratified medicine in Atopic Eczema.
Start Year 2016
 
Company Name AMLo Biosciences Limited 
Description AMLo Biosciences has identified two proteins (AMBLor) in the epidermis overlying the primary tumour that are lost in high-risk melanoma that can be assessed using standard automated immunohistochemistry, fitting seamlessly into existing pathology procedures. AMBLor has been validated in over 400 melanoma Stage I biopsies classified under the new 8th edition of AJCC staging, with known clinical outcomes. Use of this test can accurately predict melanomas that are genuinely low-risk and those that are high-risk with greater sensitivity and specificity than any other prognostic melanoma test. AMBLor also gives better prognostic information than SLNB in tumours with Breslow depth <2mm. AMLo Biosciences intends to produce a diagnostic kit to assess AMBLor in tumour tissue biopsies suitable for use in pathology labs worldwide with real potential to reduce costs to healthcare services, provide reassurance and improve patient outcomes. 
Year Established 2017 
Impact it is still too early in the company for this, they are still fundrasing.
Website https://amlo-biosciences.com/
 
Description Adopting MedTech for Patient Benefit 2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The event was delivered by the NIHR DEC Newcastle in conjunction with Newcastle Hospitals' Regional Medical Physics Department, and with the support of the Academic Health Science Network (AHSN) for North East & North Cumbria.

The event was attended by 90 delegates from across the country, and focused on helping companies to better understand the evidence required for the adoption of in vitro diagnostics (IVDs) and other medical technologies for patient benefit within the NHS.
Year(s) Of Engagement Activity 2016
URL http://www.newcastle.dec.nihr.ac.uk/adopting-medtech-2017
 
Description 'Molecular Diagnostics at Newcastle' 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The Node recently took part in the Newcastle University NAHP Industry Month with a day-long event to showcase Node-related work. The title for the event was 'Molecular Diagnostics at Newcastle' and it was held on the 2nd March 2017.
The purpose of the event was to bring industry together with the Node research community to identify potential collaboration opportunities around molecular diagnostics and image analysis.
Year(s) Of Engagement Activity 2017
URL http://www.newcastlepathnode.org.uk/2017/03/molecular-diagnostics-newcastle-node-industry-event/
 
Description EIT Health: Innovation Day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact EIT Health Innovation Day was aimed at boosting the entrepreneurial spirit among students from different disciplines and kick-starting innovation in the area of health and ageing. Inspirational speakers shared their experiences of the possibilities and rewards of health innovation and each delegate had the opportunity to develop a real viable health innovation product or idea to solve local health challenges.
EIT Health Innovation Day was a European wide event that will occured on Friday 18th November in Sweden and Denmark and Saturday 19th November in the UK.
Year(s) Of Engagement Activity 2016
URL https://www.eventbrite.com/e/eit-health-innovation-day-imperial-oxford-and-newcastle-tickets-2524062...
 
Description MRC Proximity to Discovery: UK TREND Atopic Eczema Stratified Medicine Workshop (2016 - Still Active) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Hosted by Professor Reynolds, he PtD: UK TREND atopic eczema stratified medicine workshop, built on the successful PtD: Rheumatology/Dermatology Theme week held in February 2016 and the development of an atopic eczema stratified medicine theme by UK TREND. This workshop presented an excellent opportunity to engage with key individuals and centres focused in atopic eczema research.
The significant unmet clinical need, discovery of FLG mutations predisposing to atopic eczema and particular sub-phenotypes, recent insight into other genetic and environmental risk factors and emerging biological therapies, means that atopic eczema provides an important paradigm for a stratified medicine approach. Moreover, the NIHR infrastructure and our established collaborations means that the UK is uniquely placed to deliver such an integrative and multidisciplinary project. We invited interested physicians, researchers, potential industrial partners, stake holders and patient representatives to be involved from the start. Our plans are to work together over a 12-month period to construct a credible case for support that would enable the formulation of grant applications.
Year(s) Of Engagement Activity 2017
URL http://www.newcastleptd.com/uktrend/
 
Description Taking biomarker discovery through to implementation - presentation at BIONOW Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact Bionow is a not for profit membership organisation supporting the biomedical, pharma and life sciences sectors across the North of England. Bionow does this by bringing people together at our exciting conferences and events across the North, being an advocate for the North, and providing comprehensive procurement member benefits that strengthen the competitiveness of the North's innovative life science sector.
This presentation formed part of one of their regular events aimed at increasing awareness of the sector.
Year(s) Of Engagement Activity 2018
URL https://www.bionow.co.uk/
 
Description UK TREND / Stratified Medicine follow-on Meeting, London 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact UK TREND Atopic Eczema Stratified Medicine follow-on meeting (hosted at the British Association of Dermatologists (BAD) in London). This second workshop, convened to strengthen the work of the first workshop in specific areas, has resulted in more carefully defined work streams, and led to a greater understanding of the potential contributions from collaborators (including Pharma). Collaborations with industry were strengthened (both new and existing relationships); 7 fully engaged industrial partners attended, along with 3 patient representatives, and 18 potential collaborators from other UK Universities and the NHS. Five companies were represented - Sanofi, GSK and Croda (UK), LEO Pharma (1 delegate from Denmark) and Abbvie (3 delegates from US). Expertise was shared and feedback was extremely positive (93% of the feedback graded the meeting as 'very useful' 5/5 overall). The aim of the initiative is to develop a consortium with which to gain funding to further develop projects, and this is ongoing.
Year(s) Of Engagement Activity 2017